Allogene Therapeutics Inc. (ALLO)
NASDAQ · Healthcare
Allogene Therapeutics Inc. Shareholder Equity 2019–2025
Allogene Therapeutics Inc. annual shareholder equity history from 2019 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Allogene Therapeutics Inc. shareholder equity as of December 31, 2025: 292.5M, a 30.71% decrease year-over-year.
- Allogene Therapeutics Inc. shareholder equity for 2025 were 292.5M, a 30.71% decrease from 2024.
- Allogene Therapeutics Inc. shareholder equity for 2024 were 422.2M, a 17.58% decrease from 2023.
- Allogene Therapeutics Inc. shareholder equity for 2023 were 512.2M, a 23.19% decrease from 2022.
- Allogene Therapeutics Inc. shareholder equity for 2022 were 666.9M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Allogene Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $293 |
| 2024 | $422 |
| 2023 | $512 |
| 2022 | $667 |
| 2021 | $925 |
| 2020 | $1,013 |
| 2019 | $629 |
Allogene Therapeutics Inc. Shareholder Equity — FAQ
Allogene Therapeutics Inc. (ALLO) shareholder equity over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see ALLO's shareholder equity history?
The chart and table above show Allogene Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.